AMVERSIO

This brand name is authorized in Estonia, Croatia, Lithuania

Active ingredients

The drug AMVERSIO contains one active pharmaceutical ingredient (API):

1 Betaine anhydrous UNII 3SCV180C9W - BETAINE

Betaine anhydrous was shown to lower plasma homocysteine levels in the three types of homocystinuria, i.e. CBS deficiency; MTHFR deficiency and cbl defect. The extent of this effect was dependent on the absolute degree of hyperhomocysteinemia, being higher in severe hyperhomocysteinemia. Betaine anhydrous acts as a methyl group donor in the remethylation of homocysteine to methionine in patients with homocystinuria. Read about Betaine

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
AMVERSIO Oral powder	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
A16AA06	Betaine	A Alimentary tract and metabolism → A16 Other alimentary tract and metabolism products → A16A Other alimentary tract and metabolism products → A16AA Amino acids and derivatives
Discover more medicines within A16AA06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1883594
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1094793